Are you ready for new immigration rules from 1 January 2021?

New immigration rules come into force on 1 January 2021 and everyone (excluding Irish citizens) who comes to the UK to live, work or study after 31 December 2020 will fall within the same point-based immigration rules. Automatic freedom of movement for European nationals will end. However, EEA, EU and Swiss nationals living in the UK before 31 December 2020 can apply for settled or pre-settled status under the EU … Continue reading

Employing staff in the UK? A guide for overseas companies

(Updated 9 July 2020) If you’re an overseas business looking to build a presence in the UK, or a start-up about to hire your first employee, it’s worth taking a bit of time now to understand the legal framework that will apply when employing staff in the UK. While we can’t detail all employment law in one article, we can give you an overview of key areas. First of all, the … Continue reading

Why growing US technology companies choose the UK for their European subsidiary

Despite being divided by a common language there are shared cultural roots, which make the Anglo-American relationship important both economically and politically, and thus the UK the obvious choice (despite the emerging issues of Brexit) for US companies to establish their first European subsidiary. The Magna Carta sealed in 1215 is more than just a peace treaty between the quarrelsome and unpopular King John of England and a group of rebel … Continue reading

Setting up in the UK? How to choose a branch or a subsidiary

For good reason, the UK is the No.1 destination in Europe for overseas companies to set up their European subsidiary.  In an earlier blog why growing US technology companies choose the UK, we highlighted the major reasons for this. Initially, an overseas company may ‘test the waters’ in the UK by operating from its home country, without taxable ramifications, but if successful a point will come when a more structured … Continue reading

Isosceles client VolitionRx listed on NYSE

VolutionRX on NYSE We are delighted that Isosceles client, Volition Rx, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced the pricing of its public offering of 2,475,000 shares of its common stock, at an offering price of $3.75 per share on the NYSE. VolitionRX, who will now be listed on the NYSE MKT, expects net proceeds from the … Continue reading